Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-RGX-314 gene therapy for nAMD (AAVIATE)
NCT04514653Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of surabgene lomparvovec in neovascular age-related macular degeneration (NVAMD), sponsored by AbbVie Inc.. Started Aug 2020; status: active, not recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04514653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514653.